Clinical Trial Update: Venetoclax and Lintuzumab-Ac225 in AML Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating venetoclax in combination with lintuzumab-acy225 for relapsed or adult acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Venetoclax (venetoclax)
• lintuzumab-acy225 (lintuzumab-acy225)

Snippet

Sponsor: Actinium Pharmaceuticals | Conditions: Acute Myeloid Leukemia, Relapsed Adult AML | Phase 1, Phase 2 | Status: UNKNOWN